HCW BIOLOGICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.4 USD | -0.71% |
|
-12.70% | +14.29% |
| Apr. 01 | HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 01 | HCW Biologics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 82.89 | 68.69 | 44.07 | 52.95 | - | - |
| Enterprise Value (EV) 1 | 82.89 | 68.69 | 44.07 | 52.95 | 52.95 | 52.95 |
| P/E ratio | -3.36 x | -4.56 x | -1.75 x | -2.46 x | -2.55 x | -2.22 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 10.2 x | 15.5 x | - | - | - |
| EV / Revenue | - | 10.2 x | 15.5 x | - | - | - |
| EV / EBITDA | - | -5,187,530 x | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 35,728 | 35,871 | 35,975 | 37,823 | - | - |
| Reference price 2 | 2.320 | 1.915 | 1.225 | 1.400 | 1.400 | 1.400 |
| Announcement Date | 3/29/22 | 3/28/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.1 | - | 6.722 | 2.842 | - | - | - |
| EBITDA | - | - | -13.24 | - | - | - | - |
| EBIT 1 | - | -13.37 | -15.08 | -25.72 | -23.9 | -29.6 | -38.48 |
| Operating Margin | - | - | -224.32% | -904.96% | - | - | - |
| Earnings before Tax (EBT) 1 | - | -12.86 | -14.9 | -24.99 | -23.9 | -29.6 | -38.48 |
| Net income 1 | - | -12.86 | -14.9 | -24.99 | -23.9 | -29.6 | -38.48 |
| Net margin | - | - | -221.67% | -879.53% | - | - | - |
| EPS 2 | -0.6400 | -0.6900 | -0.4200 | -0.7000 | -0.5700 | -0.5500 | -0.6300 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 5/26/21 | 3/29/22 | 3/28/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 3.118 | 0.454 | 1.809 | 1.342 | 0.0419 | 0.6228 | 0.8531 | 1.324 |
| EBITDA | - | - | - | -3.553 | -5.12 | -4.803 | -4.226 | - | - |
| EBIT 1 | -3.112 | -1.881 | -3.511 | -4.02 | -5.667 | - | -4.511 | -5.078 | -10.77 |
| Operating Margin | - | -60.33% | -773.37% | -222.2% | -422.45% | - | -724.22% | -595.23% | -813.31% |
| Earnings before Tax (EBT) 1 | -3.173 | - | -2.75 | -3.914 | -5.419 | - | -4.304 | -4.939 | -10.68 |
| Net income 1 | -3.173 | - | -3.511 | -3.914 | -5.419 | -5.071 | -4.304 | -4.939 | -10.68 |
| Net margin | - | - | -773.25% | -216.37% | -403.93% | -12,107.66% | -691.13% | -578.91% | -806.69% |
| EPS 2 | -0.0900 | -0.0600 | -0.1000 | -0.1100 | -0.1500 | -0.1400 | -0.1200 | -0.1400 | -0.3000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/29/22 | 5/13/22 | 8/12/22 | 11/7/22 | 3/28/23 | 5/9/23 | 8/11/23 | 11/14/23 | 4/1/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | 0.05 | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 5/26/21 | 3/29/22 | 3/28/23 | 4/1/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.41
USD
Average target price
4
USD
Spread / Average Target
+183.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.29% | 53.33M | |
| -3.46% | 102B | |
| +1.41% | 96.29B | |
| +2.13% | 22.18B | |
| -15.84% | 21.2B | |
| -9.21% | 18.31B | |
| -39.98% | 17.38B | |
| -14.65% | 16.36B | |
| +4.39% | 13.97B | |
| +31.35% | 12.17B |
- Stock Market
- Equities
- HCWB Stock
- Financials HCW Biologics Inc.
